Indian Pharma Status and Opportunities for Production Investment Trade

903 views

Published on

0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total views
903
On SlideShare
0
From Embeds
0
Number of Embeds
10
Actions
Shares
0
Downloads
39
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

Indian Pharma Status and Opportunities for Production Investment Trade

  1. 1. INDIAN PHARMA Status and Opportunities for Production, Investment & Trade in SME Pharma sector in India Lalit Kumar Jain Sr. Vice Chairman SME Pharma Industries Confederation (SPIC) India
  2. 2. SME Pharma Industries <ul><li>Apex body of Small and Medium scale formulators and bulk drug manufacturers </li></ul><ul><li>Over 2,300 active members besides 3,000 associate members </li></ul><ul><li>Over 7,000 in SME sector out of about 10,000 licensed drug manufacturers in India </li></ul><ul><li>SME share is 87% in production by volume and 40% share by value in the market </li></ul>
  3. 3. Situation <ul><li>India has one of the lowest per capita income in the world </li></ul><ul><li>Though prices are low but still most drugs are unaffordable, or take the bulk of the income </li></ul><ul><li>Majority of medicines are inaccessible through public health outlets </li></ul><ul><li>Perfect competition not happening in pharmaceutical trade in India, due to distorted information and perception of the market. </li></ul><ul><li>Doctors prescribe expensive branded drugs for personal gain; but price paid by poor patients. </li></ul>
  4. 4. Situation ( contd.) <ul><li>Most expensive is the most popular brand of a drug </li></ul><ul><li>Myth: medicines of lower prices cannot be of good quality </li></ul><ul><li>Distorted Media reports are planted by multinational and large firms </li></ul><ul><li>SMEs remain neglected, even after providing quality medicines at competitive prices as market is controlled by branded drugs </li></ul>
  5. 5. Quality Issue <ul><li>No unit is licensed to manufacture drugs and medicines without being GMP compliant </li></ul><ul><li>Indian GMP standards are more stringent than most developed countries </li></ul><ul><li>No facts in Media reports that India source of 40% spurious medicines in the world </li></ul><ul><li>SME manufacturing 89% of USA based companies’ drugs in India </li></ul><ul><li>No difference in branded, unbranded generics, pharmacopoeial generics drugs, except prices; since all are manufactured according to the official pharmacopoeias </li></ul>
  6. 6. Access to Quality Analytical Tools <ul><li>Dedicated centre known as SMPIC centre at NIPER, Mohali (Punjab); more than three hundred PhD thesis, about 18,000 articles in scientific journals, SciFinder (STN) facilities. </li></ul><ul><li>Instruments like 400 MHz FT – NMR (Bruker) </li></ul><ul><li>MALDI TOF-TOF (Ultra Flex, Bruker) </li></ul><ul><li>Linear Ion trap LC-MS/MS (Thermo LTQ-XL) </li></ul><ul><li>Ion trap LC – MS/MS (Finnigan Mat) GC-MS with Auto Sampler (Shimadzu) </li></ul><ul><li>GC MS/MS with Auto Sampler (Thermo) </li></ul><ul><li>GC with Head Space (Shimadzu) </li></ul><ul><li>Powder XRD (Bruker) </li></ul><ul><li>Capillary Electrophoresis (Beckman) </li></ul><ul><li>FT-IR with ATR (Nicolet), FT-IR with microscope </li></ul><ul><li>ATR, Hot plate </li></ul><ul><li>SMS system (Perkin Elmer) </li></ul><ul><li>UV-VIS Spectrophotometer etc </li></ul>
  7. 7. Quality yet Affordable SME, HOW? <ul><li>Good education and vast talented human resource pool </li></ul><ul><li>350 based API medicines, identified as essential medicines to meet 90% requirement of a patient </li></ul><ul><li>SMEs practice spot management rather than remote control management </li></ul><ul><li>Well established excipient industry </li></ul><ul><li>Only sector in India where government tender procurement prices are 1/3 of the retail market prices </li></ul>
  8. 8. Opportunities <ul><li>For venture capital investments </li></ul><ul><li>For companies abroad to cut their costs by procuring from SME sector </li></ul><ul><li>For Joint ventures </li></ul><ul><li>For upcoming markets to source technology requirements </li></ul>
  9. 9. <ul><li>THANKING YOU </li></ul><ul><li>Lalit Kumar Jain </li></ul>

×